Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 2/20 | 0.47 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.42 |
| ▸ | SGK1 | O00141 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380147 | 0.75 | PGR (0.44) | JAK1CYP17A1 | |
| SCHEMBL20297930 | 0.74 | — | — | |
| SCHEMBL3374290 | 0.74 | ACACB (0.45) | JAK1SGK1CYP17A1 | |
| SCHEMBL18343788 | 0.70 | — | — | |
| SCHEMBL527428 | 0.69 | CYP17A1 (0.67) | JAK1CYP17A1 | |
| SCHEMBL18343803 | 0.69 | — | — | |
| SCHEMBL3374824 | 0.67 | KDM1A (0.47) | XDHPFKFB3PFKFB4 | |
| SCHEMBL30009322 | 0.67 | JAK1 (0.63) | JAK1CYP17A1 | |
| SCHEMBL527268 | 0.66 | PRMT6 (0.58) | SGK1CYP17A1 | |
| SCHEMBL17629961 | 0.64 | ADH5 (1.00) | ADH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | claimed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNH2 | ADH5 3025/4885JAK1 4196/4885XDH 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.